Jefferies raises Travere Therapeutics stock price target on FSGS approval By Investing.com

Jefferies raised Travere Therapeutics’ price target to $50 from $42 and kept a Buy rating, citing low launch risk for Filspari in FSGS after FDA approval and first-quarter IgAN sales estimated at about $106 million versus $108 million consensus. The stock trades at $40.82, near its 52-week high of $43.31, while analysts also see continued profitability this year after 110% revenue growth over the last 12 months. Jefferies lifted its FSGS probability of success to 100% from 75% and HCU to 30% from 20%.

Analysis

TVTX is transitioning from a binary regulatory story to a commercial execution story, and that is usually where multiples either hold or compress. The key positive is not just label breadth; it is that the company now has a rare first-mover position in a niche where physician education, reimbursement workflows, and patient identification can be amortized across multiple indications. That creates a “shared infrastructure” effect: every incremental prescriber touched in IgAN lowers the marginal cost of launching FSGS, which should protect gross-to-net and limit the typical post-approval launch reset.

The market may still be underestimating the speed at which a second entrant can cap the upside. If the competing launch arrives with a meaningful prescription base within ~2-3 months, the issue is not total market size but share durability in the first 2-3 quarters, when payer habits and clinic protocols get set. That means the near-term risk is less about regulatory failure and more about whether TVTX can convert its lead into a sticky prescribing pattern before the competitive window closes.

The underappreciated catalyst is the pipeline re-rating from the HCU program, because a restart changes TVTX from a one-asset commercial story into a platform with option value. However, that optionality is fragile: if execution on the core renal franchise stalls, the market will likely discount pipeline value at a steep haircut. In other words, the stock can still work from here, but the path is now contingent on sustained quarterly prescription retention rather than headline approval momentum.

Key Decisions for Investors

• Stay long TVTX into the next prescription print, but size it as an execution trade rather than a pure regulatory trade; upside remains reasonable if first-quarter scripts establish a durable baseline, while downside is sharp if share gains plateau.
• Use call spreads in TVTX over the next 2-3 months to express upside with defined risk; the trade benefits from continued de-risking of the launch but avoids overpaying for volatility if competitive entry compresses the multiple.
• If TVTX rallies materially before the next quarter, consider trimming into strength and rebuying on any post-print reset; the stock is likely to trade on prescription momentum more than on the already-validated approval news.
• Watch competitor launch data closely and, if early prescriptions inflect faster than expected, pair long TVTX with short the more mature renal incumbent basket to isolate execution dispersion rather than make a single-name directional bet.
• Do not chase the move on headline price-target upgrades alone; the better entry is any pullback tied to broader biotech weakness, since the next catalyst is data flow over the coming 4-8 weeks, not a further regulatory event.